<?xml version="1.0" encoding="UTF-8"?><html>
   <div tagx="ui">1745-6215-16-9</div>
   <div tagx="ji">1745-6215</div>
   <head>
      <div tagx="dochead">Study protocol</div>
      <div tagx="bibl">
         <div tagx="title">
            <p>A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate
               added to treatment as usual in early schizophrenia: study protocol for a randomised
               controlled trial
            </p>
         </div>
         <ul tagx="aug">
            <li tagx="au">
               <span tagx="snm">Chaudhry</span>
               <span tagx="mi">B</span>
               <span tagx="fnm">Imran</span>
               <span tagx="insr"></span>
               <a href="ibchaudhry@btinternet.com">ibchaudhry@btinternet.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Husain</span>
               <span tagx="fnm">Nusrat</span>
               <span tagx="insr"></span>
               <a href="nusrat.husain@manchester.ac.uk">nusrat.husain@manchester.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">ur Rahman</span>
               <span tagx="fnm">Raza</span>
               <span tagx="insr"></span>
               <a href="razaur@yahoo.com">razaur@yahoo.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Husain</span>
               <span tagx="mnm">Omair</span>
               <span tagx="fnm">Mohammed</span>
               <span tagx="insr"></span>
               <a href="so_moo@hotmail.com">so_moo@hotmail.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Hamirani</span>
               <span tagx="mi">M</span>
               <span tagx="fnm">Mohammed</span>
               <span tagx="insr"></span>
               <a href="mmmham@yahoo.com">mmmham@yahoo.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Kazmi</span>
               <span tagx="fnm">Ajmal</span>
               <span tagx="insr"></span>
               <a href="kazmiajmal@yahoo.com">kazmiajmal@yahoo.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Baig</span>
               <span tagx="fnm">Shakeel</span>
               <span tagx="insr"></span>
               <a href="brukarachi@yahoo.com">brukarachi@yahoo.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Haddad</span>
               <span tagx="mi">M</span>
               <span tagx="fnm">Peter</span>
               <span tagx="insr"></span>
               <a href="peter.haddad@gmw.nhs.uk">peter.haddad@gmw.nhs.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Buch</span>
               <span tagx="mi">H</span>
               <span tagx="fnm">Maya</span>
               <span tagx="insr"></span>
               <a href="m.buch@leeds.ac.uk">m.buch@leeds.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Qureshi</span>
               <span tagx="fnm">Inti</span>
               <span tagx="insr"></span>
               <a href="Inti.Qurashi@merseycare.nhs.uk">Inti.Qurashi@merseycare.nhs.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Mehmood</span>
               <span tagx="fnm">Nasir</span>
               <span tagx="insr"></span>
               <a href="nasir.mehmood@manchester.ac.uk">nasir.mehmood@manchester.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Kiran</span>
               <span tagx="fnm">Tayyeba</span>
               <span tagx="insr"></span>
               <a href="tayyaba.kiran@pill.org.pk">tayyaba.kiran@pill.org.pk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Fu</span>
               <span tagx="fnm">Bo</span>
               <span tagx="insr"></span>
               <a href="Bo.fu@manchester.ac.uk">Bo.fu@manchester.ac.uk</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Afsar</span>
               <span tagx="fnm">Salahuddin</span>
               <span tagx="insr"></span>
               <a href="salahuddinafsar@hotmail.com">salahuddinafsar@hotmail.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Deakin</span>
               <span tagx="fnm">Bill</span>
               <span tagx="insr"></span>
               <a href="bill.deakin@manchester.ac.uk">bill.deakin@manchester.ac.uk</a>
            </li>
         </ul>
         <ul tagx="insg">
            <li tagx="ins">
               <p>University of Manchester &amp; Lancashire Care Early Intervention Service, Manchester,
                  UK
               </p>
            </li>
            <li tagx="ins">
               <p>Dow University of Health Sciences, Karachi, Pakistan</p>
            </li>
            <li tagx="ins">
               <p>Southwest London and St George’s NHS Trust, London, UK</p>
            </li>
            <li tagx="ins">
               <p>Abbassi Shaheed Hospital, Karachi, Pakistan</p>
            </li>
            <li tagx="ins">
               <p>Pakistan Institute of Leaning and Living, Karachi, Pakistan</p>
            </li>
            <li tagx="ins">
               <p>Baqai University, Karachi, Pakistan</p>
            </li>
            <li tagx="ins">
               <p>University of Manchester &amp; Greater Manchester West Mental Health NHS Foundation Trust,
                  Manchester, UK
               </p>
            </li>
            <li tagx="ins">
               <p>University of Leeds, Leeds, UK</p>
            </li>
            <li tagx="ins">
               <p>Mersey Care NHS Trust, Liverpool, UK</p>
            </li>
            <li tagx="ins">
               <p>University of Manchester, Manchester, UK</p>
            </li>
         </ul>
         <span tagx="source">Trials</span>
         <span tagx="issn">1745-6215</span>
         <span tagx="pubdate">2015</span>
         <span tagx="volume">16</span>
         <span tagx="issue">1</span>
         <span tagx="fpage">9</span>
         <a href="http://www.trialsjournal.com/content/16/1/9">http://www.trialsjournal.com/content/16/1/9</a>
         <div tagx="xrefbib">
            <div tagx="pubidlist">
               <span tagx="pubid">10.1186/1745-6215-16-9</span>
               <span tagx="pubid">25563714</span>
            </div>
         </div>
      </div>
      <div tagx="history">
         <span tagx="rec">
            <div tagx="date">
               <span tagx="day">20</span>
               <span tagx="month">5</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="acc">
            <div tagx="date">
               <span tagx="day">16</span>
               <span tagx="month">12</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="pub">
            <div tagx="date">
               <span tagx="day">7</span>
               <span tagx="month">1</span>
               <span tagx="year">2015</span>
            </div>
         </span>
      </div>
      <div tagx="cpyrt">
         <span tagx="year">2015</span>
         <div tagx="collab">Chaudhry et al.; licensee BioMed Central.</div>
         <div tagx="note">This is an Open Access article distributed under the terms of the Creative Commons
            Attribution License (
            <a href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided
            the original work is properly credited. The Creative Commons Public Domain Dedication
            waiver (
            <a href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated.
         </div>
      </div>
      <div id="abstract" tag="abstract">
         <div id="">
            <div tagx="st">
               <h2>Abstract</h2>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Background</h3>
               </div>
               <p>Methotrexate is a commonly used anti-inflammatory and immunosuppressive drug. There
                  is growing evidence that inflammatory processes are involved in the pathogenesis of
                  schizophrenia. In our recent randomised double-blind placebo-controlled clinical trial
                  in Pakistan and Brazil, the addition of minocycline (antibiotic and anti-inflammatory
                  drug) for 1 year to treatment as usual reduced negative symptoms and improved some
                  cognitive measures. A meta-analysis of cytokine changes in the peripheral blood has
                  identified IL-2, IFN-gamma, TNF-alpha and soluble IL-2 receptor as trait markers of
                  schizophrenia because their levels were elevated during acute exacerbations and reduced
                  in remission. This suggests immune activation and an inflammatory syndrome in schizophrenia.
                  Based on the evidence of the strong anti-inflammatory properties of methotrexate,
                  we propose that low-dose methotrexate may be an effective therapy in early schizophrenia.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Methods/Design</h3>
               </div>
               <p>This is a double-blind placebo-controlled study of methotrexate added to treatment
                  as usual for patients suffering from schizophrenia, schizoaffective disorder, psychosis
                  not otherwise specified or schizophreniform disorder. This will be with 72 patients,
                  36 in each arm over 3 months. There will be screening, randomisation and follow-up
                  visits. Full clinical assessments will be carried out at baseline, 2, 4, 8 and 12 weeks.
                  Social and cognitive assessments will be carried out at baseline and 12 weeks. Methotrexate
                  will be given at a dose of 10 mgs orally once a week for a 3-month period.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Discussion</h3>
               </div>
               <p>Evidence suggests inflammatory processes are involved in the pathogenesis of schizophrenia
                  and anti-inflammatory treatments have shown to have some beneficial effects. Methotrexate
                  is a known immunosuppressant and anti-inflammatory drug. The aim of this study is
                  to establish the degree of improvement in positive and negative symptoms, as well
                  as cognitive functioning with the addition of methotrexate to treatment as usual.
               </p>
               <p>ClinicalTrials.gov identifier: 
                  <div tagx="a">NCT02074319</div> (24 February 2014).
               </p>
            </div>
         </div>
      </div>
   </head>
   <div id="">
      <div tagx="st">
         <h2>Background</h2>
      </div>
      <p>Methotrexate (MXTis a commonly used anti-inflammatory and immunosuppressive drug,
         originally developed and continuing to be used for chemotherapy either alone or in
         combination with other agents. It is used as a treatment for some autoimmune diseases,
         including arthritis, psoriasis, psoriatic arthritis, lupus and Crohn's disease. Low-dose
         MXT has been used for treatment of rheumatoid arthritis for almost 50 years, is very
         effective and is recognised as treatment of choice and first-line therapy for many
         patients 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>. MXT is thought to affect cancer and rheumatoid arthritis by two different pathways.
         For cancer, MXT competitively inhibits dihydrofolate reductase (DHFR), an enzyme that
         participates in the tetrahydrofolate synthesis 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">2</span>
         </span>. However, in rheumatoid arthritis it most likely acts by the inhibition of enzymes
         involved in purine metabolism or by inhibition of T cell activation 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">3</span>
         </span>.
      </p>
      <p>There has been interest in using MXT in other conditions where excessive immune activation
         and inflammatory mediators are believed to be involved in the pathogenesis. For example,
         Gong 
         <i>et al</i>. 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">4</span>
         </span> showed that in cardiac failure patients, low-dose MXT has significant anti-inflammatory
         effects and improved functional outcomes and quality of life. In an animal model of
         cardiac failure Zhang 
         <i>et al</i>. 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">5</span>
         </span> showed that MXT has the ability to regulate inflammatory responses and improve cardiac
         function, hence contributing to prevent the development of post-myocarditis dilated
         cardiomyopathy.
      </p>
      <p>There is growing evidence that inflammatory processes are involved in the pathogenesis
         of schizophrenia 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">6</span>
         </span>. In our recent randomised double-blind placebo-controlled clinical trial in Pakistan
         and Brazil, funded by the Stanley Medical Research Institute (SMRI), the addition
         of minocycline (an antibiotic and anti-inflammatory drug) for 1 year to treatment
         as usual (TAU) reduced negative symptoms and improved some cognitive measures 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">7</span>
         </span>. Several studies have noted increase in peripheral inflammatory cytokines, such as
         IL-1, IL-2, IL-6, and TNF-alpha 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">8</span>
         </span>. In the brain, cytokines seem to be involved in regulating the action of several
         neurotransmitters, such as serotonin, noradrenalin, dopamine, and glutamate. The interaction
         of cytokines with dopamine and glutamate seems to be especially relevant to the pathophysiology
         of schizophrenia 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">9</span>
         </span>.
      </p>
      <p>A meta-analysis of cytokine changes in the peripheral blood has identified IL-12,
         IFN-gamma, TNF-alpha, and soluble IL-2 receptor (sIL-2R) as trait markers of schizophrenia
         because their levels were elevated during acute exacerbations and remission 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">10</span>
         </span>. An extensive meta-analysis by Potvin 
         <i>et al</i>. 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">8</span>
         </span> reports significant increases in 
         <i>in vivo</i> peripheral levels of IL-1RA, sIL-2R, and IL-6 in schizophrenia patients, supporting
         evidence of immune activation and an inflammatory syndrome in schizophrenia. Studies
         show that IL-6 mediates the deleterious effects of noncompeting N-methyl-D-aspartate
         (NMDA) antagonists on cortical interneurons 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">11</span>
         </span> and cytokines have an impact on the regulation of neuroplasticity, cellular resilience,
         and apoptosis control 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">12</span>
         </span>. TNF-alpha seems to inhibit brain-derived neurotrophic factor (BDNF) release, compromising
         the protective effect of this neurotrophin.
      </p>
      <p>A number of studies report that treatment with antipsychotic drugs affects the cytokine
         network 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">13</span>
         </span>. This supports the rationale that the influence of antipsychotics on the cytokine
         systems may be responsible for their clinical efficacy in schizophrenia. Peripheral
         immune processes may be mirrored in the brain by microglial cells 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">6</span>
         </span>. The 'microglia hypothesis of schizophrenia' suggests that the release of proinflammatory
         cytokines, kynurenines, nitric oxide (NO) and reactive oxygen species (ROS) by activated
         microglia might cause neuronal degeneration, white matter abnormalities and decreased
         neurogenesis 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">14</span>
            <span tagx="abbr">15</span>
            <span tagx="abbr">16</span>
         </span>. Recent positron emission tomography (PET) studies during acute psychotic episodes
         in early schizophrenia suggest an activation of microglia 
         				
         <span tagx="abbrgrp">
            <span tagx="abbr">17</span>
            <span tagx="abbr">18</span>
         </span>.
      </p>
      <p>If MXT, which is already on the market for the treatment of heart disease, cancer
         and rheumatic diseases, proves effective for reducing symptoms of schizophrenia then
         this could transform the suffering evidenced by patients which severely impairs their
         quality of life. Targeting the inflammatory response is a major focus of novel drug
         development especially relevant to the treatment of Treatment Resistant Schizophrenia
         (TRS). Based on the evidence of strong anti-inflammatory properties of MXT, we propose
         that low-dose MXT may be an effective therapy in early schizophrenia.
      </p>
      <div id="">
         <div tagx="st">
            <h3>AIMS</h3>
         </div>
         <p>To test the prediction that addition of MXT to treatment as usual (TAU) for patients
            with early schizophrenia will result in following outcomes:
         </p>
         <p>
            <div tagx="monospace">○</div> To demonstrate that the trial design is acceptable to participants including randomisation
            to x arms
         </p>
         <p>
            <div tagx="monospace">○</div> To demonstrate that the interventions are acceptable to participants and indicate
            likely attrition rates and tolerabilityImprovement in negative symptoms
         </p>
         <p>
            <div tagx="monospace">○</div> Improvement in positive symptoms
         </p>
         <p>
            <div tagx="monospace">○</div> Improvement in social functioning
         </p>
         <p>
            <div tagx="monospace">○</div> Improvement in cognitive functions
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Methods/Design</h2>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Overview</h3>
         </div>
         <p>This is a double-blind placebo-controlled trial of MXT added to TAU for patients suffering
            from schizophrenia, schizoaffective disorder, psychosis not otherwise specified or
            schizophreniform disorder. The ethical approval covering all sites was obtained from
            the Research and Ethics Committee of the Pakistan Institute of Learning and Living
            and was submitted to the funding body, SMRI (Project Reference: PILL/SMRI/12627).
            Patients will be recruited from inpatient and outpatient settings. They will initially
            be approached by the treating psychiatrists and the multi-disciplinary teams (MDT).
            Patients will continue to take TAU during the trial. Although, the study assessments
            will be carried out by the research assistants (RAs), the responsible clinician (consultant
            psychiatrist) will remain in charge of the overall treatment. Antipsychotic dosage
            will be kept constant, unless clinically warranted, any changes will be recorded on
            monthly reviews.
         </p>
         <p>After consenting to take part in the study, 72 patients will be randomised into two
            groups: 36 in each arm over the 3-month period. Full clinical assessments will be
            carried out at baseline, 2, 4, 8 and 12 weeks. Social and cognitive assessments will
            be carried out at baseline and 12 weeks (Table 
            					
            <span tagx="tblr">1</span>). MXT once a week or placebo once a week will be added to TAU. Tolerability will
            be assessed by self report. During the course of the study the patient will also have
            additional support by doctors and RAs from the research team and continued support
            from their mental health care team. If necessary, members of the research team will
            be available 24 hours a day, 7 days a week.
         </p>
         <table>
            <div tagx="title">
               <p>Table 1</p>
            </div>
            <caption>
               <p>
                  <b>Schedule of assessments</b>
               </p>
            </caption>
            <tgroup>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <thead>
                  <tr>
                     <td>
                        <p>
                           <b>Assessment</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Who</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>When</b>
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>
                           <b>Patient</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Research assistants</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>RMO team</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Screening</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Randomisation</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Week 2</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Week 4</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Week 8</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Week 12</b>
                        </p>
                     </td>
                  </tr>
               </thead>
               <div tagx="tfoot">
                  <p>
                     <sup>a</sup>Lab screen includes FBC, renal function and liver functions tests. Patients will continue
                     to have these tests at 2-weekly intervals if there are abnormalities on the 6-week
                     blood tests that do not warrant withdrawal from the study. These blood tests are also
                     repeated 4 weeks after finishing the study. Additional blood tests are conducted at
                     baseline and 12 weeks.
                  </p>
                  <p>
                     <i>Abbreviations</i>: 
                     <i>BMI</i> body mass index, 
                     <i>BP</i> blood pressure, 
                     <i>CGI</i> Clinical Global Impression, 
                     <i>FBC</i> full blood count, 
                     <i>GAF</i> Global Assessment of Functioning, 
                     <i>HR</i> heart rate, 
                     <i>PANNS</i> Positive and Negative Syndrome Scale, 
                     <i>QOL</i> quality of life, 
                     <i>RMO</i> resident medical officer, 
                     <i>SCID</i> Structured Clinical Interview for DSM-IV.
                  </p>
               </div>
               <tbody>
                  <tr>
                     <td>
                        <p>Case note review</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>SCID</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>Drug treatment history</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Medical history</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>Physical exam</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Body weight and BMI</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>BP and HR</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Lab screen
                           <sup>a</sup>
                        </p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Pregnancy screen (urine)</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Inclusion criteria</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>Exclusion criteria</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>Withdrawal criteria</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>Consent</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>PANNS</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>CGI</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>GAF</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>QOL</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Social function scale</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Cognitive assessments</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Antipsychotic side-effects</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Side-effects</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>Spontaneously reported adverse effects and</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td></td>
                  </tr>
                  <tr>
                     <td>
                        <p>methotrexate toxicity check list</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Compliance monitoring</p>
                     </td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td></td>
                     <td></td>
                     <td></td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                     <td>
                        <p>x</p>
                     </td>
                  </tr>
               </tbody>
            </tgroup>
         </table>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Allocation</h3>
         </div>
         <p>In this study patients will be allocated to treatment group according to a randomised
            permuted blocks algorithm, after stratification by centre. Allocation will be determined
            in Manchester by pseudo-random number generation by the trial statistician. The results
            will be conveyed to the trial pharmacist so that medication can be given to participants
            without anyone else on the team being aware of the allocation (that is, double-blind).
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Blinding</h3>
         </div>
         <p>This is a double-blind, randomised, placebo-controlled feasibility study. Random allocation
            to treatments will be undertaken by a statistician who will have no knowledge of the
            patient characteristics. The details of the allocation will be concealed from the
            research team until all data collection has been completed. Blinding of participants
            and treating physicians to allocation status will be assured by identical capsule
            appearance, by identical labelling between placebo and the active drugs (apart from
            labels identifying the patient). Blinding of the capsules, packaging and labelling,
            will be undertaken by pharmacist independent of the study. Study investigators and
            researchers administering the assessment measures will not be aware of the study drug
            allocated to the individual. In the event a patient develops any side- effects, where
            drug unblinding is required, the treating physician will be made aware of the study
            drug, possible side-effects and make the appropriate decision whether to continue
            or discontinue the drug. The safety and wellbeing of the patient will be paramount
            at all times.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Statistical consideration</h3>
         </div>
         <p>Our sample size consideration is based on the hypothesis that there will be a significant
            difference in changes from baseline to end-point on the clinical outcome measures
            and the cognitive function measures between the MXT group and the TAU group. With
            32 participants per group, this study will have 80% power to detect a standardised
            effect size of 0.53 (medium by the definition of Cohen) by using a 2-sided significant
            level of 0.20. As this is a preliminary study, we used a less stringent significance
            level so as not to miss a promising effect rather than being too concerned by false
            positives. The estimated loss to follow-up rate is 10% and, therefore, a total of
            72 patients (36 MXT, 36 TAU) are needed. Our sample size is adequate to estimate the
            parameters of acceptability and tolerability to the necessary degree of precision.
         </p>
         <p>The planned analyses will be by intention-to-treat (ITT). Careful consideration will
            be given to the potential biases arising from the drop-out and missing data. Group
            differences in the change of clinical outcome measures and cognitive function measures
            at baseline to 12 weeks will be assessed using the 
            <i>t</i>-test or analysis of covariance (ANCOVA) adjusting for baseline differences. For repeatedly
            measured clinical outcomes at baseline, 2, 4, 8 and 12 weeks, we will also use generalised
            estimating equations (GEE) to estimate the effect of MXT treatment on longitudinal
            outcomes, including baseline values and time terms as covariates. GEE offers a robust
            method to take account of the within-subject correlation in longitudinal data.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Inclusion/Exclusion criteria</h3>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Inclusion criteria</h4>
            </div>
            <p>• Signed informed consent, indicating that the subject understood the purpose of and
               procedures required for the study, before the initiation of any study specific procedures
            </p>
            <p>• Aged 18 to 35 years</p>
            <p>• 
               <i>Diagnostic and Statistical Manual-IV</i> (DSM-IV) diagnosed schizophrenia, schizoaffective disorder, psychosis not otherwise
               specified or schizophreniform disorder
            </p>
            <p>• Early schizophrenia (within first 5 years of diagnosis)</p>
            <p>• Competent and willing to give informed consent</p>
            <p>• Medication remained stable 4 weeks prior to baseline</p>
            <p>• Able to take oral medication and likely to complete the required evaluations</p>
            <p>• Female participants of child-bearing capability must be willing to use adequate
               contraceptives for the duration of the study, and willing to have a pregnancy test
               pre- treatment and at 10-weekly intervals while on study medication. Adequate contraception
               is defined as use of contraceptive double barrier system (that is condom and spermicide)
               or contraceptive implant, oral contraceptive or injected depot contraceptive plus
               other form of contraceptive, that is a condom. Females will be considered incapable
               of child-bearing if they are 1 year post-menopausal or irreversibly surgically sterilised
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Exclusion criteria</h4>
            </div>
            <p>• Violation of any inclusion criteria</p>
            <p>• Failure to perform screening or baseline examinations</p>
            <p>• Relevant 
               <i>International Statistical Classification of Diseases and Related Health Problems</i> (ICD-10) organic brain disease or neurological diagnoses (including electrocardiogram
               (ECG) conduction abnormalities, neurological disorder, or an active seizure)
            </p>
            <p>• Patients with liver disease and polyarthritis</p>
            <p>• Patients who will meet the criteria for a DSM-IV-text revision(TR) diagnosis of
               alcohol or substance abuse (other than for nicotine) within the last month or the
               criteria for DSM-IV-TR alcohol or substance dependence (other than for nicotine) within
               the last 6 months
            </p>
            <p>• Any change of psychotropic medications within the previous 4 weeks</p>
            <p>• Pregnant or lactating women and those of reproductive age without adequate contraception</p>
            <p>• Relevant medical illness will be determined in the first instance by asking the
               patient's mental health care team if the patient has any medical condition/problems.
               After consent has been obtained the research nurse/research doctor will then have
               access to the patients’ notes and will assess patient eligibility to take part in
               the clinical trial by scrutinising the patients’ past medical history, most recent
               blood results, ECGs, as well as any physical tests that have been performed on the
               patient. If there are any deviations from the ‘norm’ the investigators will assess
               the eligibility of the individual patient. Automatic contraindications will include
               significantly impaired renal function, significantly impaired hepatic function and
               pre-existing blood dyscrasias, such as significant marrow hypoplasia, leukopenia,
               thrombocytopenia or anemia.
            </p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Interval of assessments</h3>
         </div>
         <p>There will be a screening, a randomisation and follow-up visits. Full clinical assessments
            (Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI), Global
            Assessment of Functioning (GAF), Social Functioning Scale (SFS) and Quality of Life
            Scale (QLS)) will be carried out at baseline, 2, 4, 8 and 12 weeks. Social and cognitive
            assessments (CogState, IQ using Wechsler Adult Intelligence Scale (WAIS) block design,
            Coughlan Learning Task, Stroop Task, Verbal Fluency) will be carried out at baseline
            and 12 weeks. The clinical interview and ratings will take approximately 50 minutes.
            The neuropsychological assessments will take about 60 to 80 minutes. The patients
            will primarily be seen at their treating team’s base. In special circumstances, if
            requested by the treating team or patient, the RAs can visit at home.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>RA training and inter-rater reliability</h3>
         </div>
         <p>Research assistants in Karachi were trained in Structured Clinical Interview for DSM-IV
            (SCID), clinical and neuropsychological assessments at the University of Manchester
            for a previous SMRI-funded study. Inter-rater reliability sessions will be conducted
            by local principle investigators (PIs) using training videos.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Treatments</h3>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Treatment as usual</h4>
            </div>
            <p>The patients can be on either first or second generation antipsychotic medications,
               as deemed suitable by the responsible psychiatrist. From our experience with previous
               studies there is no major advantage of one generation of drugs over the other.
            </p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Study drug dosage</h3>
         </div>
         <p>MXT 7.5 mgs orally once a week) for a 3-month period as an augmentation agent with
            TAU. All participants will also take folic acid 5 mgs/day orally for 6 days a week
            (except the day MXT is given), which is routinely given with MXT to prevent vitamin
            deficiencies.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Outcome measures for tolerability and acceptability</h3>
         </div>
         <p>The definition of tolerability refers to adverse events. An adverse event is the development
            of an undesirable medical condition or the deterioration of a pre-existing medical
            condition following or during exposure to a pharmaceutical product, whether or not
            considered causally related to the product.
         </p>
         <p>At each clinical assessment (baseline, 2, 4, 8 and 12 weeks and early exit from the
            study) we will collect spontaneously reported adverse effects and also administer
            an adverse effect check list covering 8 key symptoms/signs of MXT toxicity (rash,
            oral ulceration, nausea and vomiting, diarrhea, new or increasing dyspnea, new or
            increasing dry cough, severe sore throat, abnormal bruising). If any of these eight
            symptoms are present MXT will be withheld until the case has been discussed with the
            onsite investigator. In addition, severe sore throat or abnormal bruising will lead
            to an urgent full blood count (FBC) being conducted, the result of which will be considered
            by the investigator in reaching a decision on the patient continuing in the trial.
            The routine blood tests at baseline, 2, 4, 6 and 12 weeks will be reviewed by the
            site investigator within 4 days of being taken and the patient withdrawn from the
            study if any indices give cause for concern (that is are outside pre-specified parameters).
         </p>
         <p>Acceptability is defined as treatment discontinuation in terms of the number of patients
            who terminated the study early (drop-outs) for any reason following randomisation.
            We will request an exit interview with all participants who did not complete the study
            to explore tolerability and acceptability.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Clinical outcome measures</h3>
         </div>
         <p>1. Negative symptom severity as defined by negative syndrome subscale score on the
            PANSS and/or Negative Symptom Assessment Scale;
         </p>
         <p>2. Full PANSS and positive syndrome subscale score 
            					
            <span tagx="abbrgrp">
               <span tagx="abbr">19</span>
            </span>
         </p>
         <p>3. CGI</p>
         <p>4. Functional outcome:</p>
         <p>• GAF from DSM-IV (2000) 
            					
            <span tagx="abbrgrp">
               <span tagx="abbr">20</span>
            </span>
         </p>
         <p>• SFS self-rating in seven domains 
            					
            <span tagx="abbrgrp">
               <span tagx="abbr">21</span>
            </span>
         </p>
         <p>• QLS for treatment effects related to deficit or negative symptoms 
            					
            <span tagx="abbrgrp">
               <span tagx="abbr">22</span>
            </span>
         </p>
         <div id="">
            <div tagx="st">
               <h4>Cognitive function measures</h4>
            </div>
            <p>We will use pencil and paper tests and CogState; measuring all seven domains recommended
               by MATRICS (NIMH initiative). These domains include speed processing, attention/vigilance,
               working memory (nonverbal and verbal), verbal learning, visual learning, reasoning
               and problem solving and social cognitions. We will use the following tests:
            </p>
            <p>1. IQ: using WAIS block design</p>
            <p>2. Stroop Task, for divided attention and processing speed</p>
            <p>3. Coughlan Learning Task (Verbal and Visual)</p>
            <p>4. Verbal Fluency (words and categories)</p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Side-effects</h3>
         </div>
         <p>Self reported antipsychotic side-effects: Antipsychotic Non-Neurological Side-Effects
            Rating Scale (ANNSERS) 
            					
            <span tagx="abbrgrp">
               <span tagx="abbr">23</span>
            </span>.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Safety assessments</h3>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Medical history</h4>
            </div>
            <p>The primary purpose of screening is to check for inclusion and exclusion criteria.
               The RAs will arrange for a doctor to complete checklists for medical history, review
               of systems and physical exam. These assessments will be repeated after 3 months in
               the trial or at the time of withdrawal from the study.
            </p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Physical assessments</h3>
         </div>
         <p>ECG, blood pressure, pulse, height, waist, weight and body mass index (BMI).</p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Blood investigations</h3>
         </div>
         <p>FBC, erythrocyte sedimentation rate, LFTs, lipid profile, urea, electrolytes, cytokines
            and C-reactive protein.
         </p>
         <p>Patients will have FBC and renal and LFTs before starting treatment and repeated at
            2, 4, 6 and 12 weeks. Remaining investigations will be at baseline and 12 weeks. Patients
            will be advised to report all symptoms and signs suggestive of toxicity and infection,
            especially sore throat. Patients will continue to have a 2-weekly FBC after 6 weeks
            if there are abnormalities on the 6-week FBC that do not warrant withdrawal from the
            study. For patient safety, full blood monitoring will be repeated at 4 weeks after
            finishing the study, at week 16.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Additional safety measures</h3>
         </div>
         <p>1. At each clinical assessment (baseline, 2, 4, 8 and 12 weeks and early exit from
            the study) we will collect spontaneously reported adverse effects and also administer
            an adverse effect check list covering 8 key symptoms/signs of MXT toxicity (rash,
            oral ulceration, nausea and vomiting, diarrhea, new or increasing dyspnea, new or
            increasing dry cough, severe sore throat, abnormal bruising). If any of these eight
            symptoms are present MXT will be withheld until the case has been discussed with the
            onsite investigator. In addition, severe sore throat or abnormal bruising will lead
            to an urgent FBC being conducted the result of which will be considered by the investigator
            in reaching a decision on the patient continuing in the trial.
         </p>
         <p>2. The routine blood tests at baseline, 2, 4, 6 and 12 weeks will be reviewed by the
            site investigator within 4 days of being taken and the patient withdrawn from the
            study if any indices give cause for concern (that is are outside pre-specified parameters).
         </p>
         <p>3. Our administration of a symptoms checklist and monitoring of FBC, LFTs and renal
            function is similar to monitoring advised in the UK (
            <a href="http://cks.nice.org.uk/dmards#!scenario:8">http://cks.nice.org.uk/dmards#!scenario:8</a>).
         </p>
         <p>4. Folic acid, 5 mg once weekly will be given, not on the same day as MXT, preferably
            the day after 
            					
            <span tagx="abbrgrp">
               <span tagx="abbr">24</span>
            </span>. Folic acid reduces toxic effects of MXT and improves continuation of therapy and
            compliance 
            					
            <span tagx="abbrgrp">
               <span tagx="abbr">25</span>
               <span tagx="abbr">26</span>
            </span>. There is also evidence that increasing folate levels improves outcomes in schizophrenia
            
            					
            <span tagx="abbrgrp">
               <span tagx="abbr">27</span>
            </span>.
         </p>
         <p>5. Given that participating psychiatrists will have little or no experience in prescribing
            MXT, we will ensure that there is an on-call system such that all investigators can
            get immediate expert advice from a physician in Pakistan who is experienced in prescribing
            and monitoring methotrexate.
         </p>
         <p>6. MXT will be dispensed 2-weekly throughout the study to limit the supply participants
            have, facilitate monitoring and adherence. The label will state: ‘Take once a week’.
         </p>
         <p>7. Participants will all have an information leaflet with safety information.</p>
         <p>8. The patients will have access to their RA at all times, who will be able to contact
            the research team medical staff 24 hours a day, 7 days a week for support and advice.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Study procedures</h3>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Recruitment</h4>
            </div>
            <p>Responsible consultant psychiatrists will be approached and asked if they will allow
               their patients to take part in this research study. The research clinician, initially,
               will approach the clinical teams to inform them about the research study, specifically
               with regard to inclusion and exclusion criteria. The research clinician will establish
               a good working relationship with individual clinical teams. With regular contact,
               either by phone or by visits, patients who are suitable to take part in the research
               study will be identified in collaboration with the treating teams. The consultant
               psychiatrist will then introduce the study to the patient if they meet the inclusion
               criteria, are clinically stable, and the MDT agree the patient could be a possible
               participant. With the patient’s consent, the research clinician will visit them and
               explain the research study verbally as well as provide them with the written information.
               At least 24 hours will be given to the patient to allow time to read and understand
               the patient information sheet. If they are willing to take part, a meeting will be
               organised with the patient in order to obtain consent for the research and also consent
               for the research team to have access to their medical notes.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Screening visit</h4>
            </div>
            <p>At the screening visit a confirmation of a patient’s suitability for the trial will
               be carried out. The patient will be assessed against the inclusion/exclusion criteria,
               have a confirmation of their diagnosis, confirmation of consent to take part in the
               trial and pregnancy testing if appropriate. The RAs will arrange for a doctor to complete
               a checklist for medical history, physical examination and hematological investigations.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Randomisation visit</h4>
            </div>
            <p>The baseline clinical and neuropsychological measures will be completed and the patient
               will be randomised to one of the two arms, allocated a unique identification number
               and will commence study drug treatment.
            </p>
            <p>The patient will be given a study information card explaining that they are in a clinical
               study and are taking MXT or placebo; the telephone numbers of the senior research
               clinicians, the clinical trial office and the name of the local PIs will be provided.
            </p>
            <p>In accordance with (International Conference for Harmonisation) Good Clinical Practice
               ((ICH) GCP) (1996) 
               						
               <span tagx="abbrgrp">
                  <span tagx="abbr">28</span>
               </span>, copies of all the above will be placed in the patient’s medical notes along with
               contact names and telephone numbers.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Follow-up visits</h4>
            </div>
            <p>The first follow-up visit will be after 2 weeks of the randomisation to complete clinical
               assessments. There will be subsequent visits at week 4, 8 and 12. The study drugs
               will be dispensed from the local pharmacy departments. The RAs will collect and deliver
               these to the patient at a previously agreed upon location. This will give the opportunity
               for the research team to closely monitor the patient’s physical and mental health,
               side-effects and compliance.
            </p>
            <p>Female patients of childbearing capacity taking part in the clinical trial will have
               a pregnancy test at baseline, 8 and 12 weeks. If they should become pregnant during
               the course of the study, they will be withdrawn from the study.
            </p>
            <p>During the course of the study the patient’s individual consultant and mental health
               care team will be responsible for their overall care. If any concerns do occur with
               regard to the research study, the research team will be contactable to discuss these
               concerns 24 hours a day, 7 days a week.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Final visit</h4>
            </div>
            <p>At this visit all clinical, social, cognitive, physical and hematological assessments
               will be completed. Trial medication will cease.
            </p>
            <p>At all visits the patient’s cumulative clinical drug treatment will be updated from
               the case notes.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Study coordination</h4>
            </div>
            <p>Weekly meetings by local investigators will occur to coordinate the study. The chief
               investigator will conduct 2-weekly tele- and video-conference meeting. The access
               grid facility at the University of Manchester will also be available.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Patient safety</h4>
            </div>
            <p>Day-to-day care will remain the responsibility of the consultant in charge of the
               patient. However, study related safety concerns will be the responsibility of the
               local PI. The PIs and the co-investigators will be contactable at any time via the
               clinical trials office or/and through the senior research clinicians.
            </p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Patient withdrawal</h4>
            </div>
            <p>Patients may be withdrawn from the treatment study for the following reasons:</p>
            <p>1. At their own request.</p>
            <p>2. At the discretion of the investigator.</p>
            <p>3. If any patients suffers a serious adverse event, or moderate to severe adverse
               drug reaction.
            </p>
            <p>4. Any patients who meet the criteria for insufficient compliance. This is defined
               as either taking less than 75% of antipsychotic or trial medication between assessment
               points at baseline, 6 weeks and 12 weeks; or missing trial medications or antipsychotic
               medication altogether for 7 days or more at any period.
            </p>
            <p>5. If a patient becomes pregnant.</p>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Ethical and regulatory standards</h4>
            </div>
            <div id="">
               <div tagx="st">
                  <h5>Local Research Ethics Committee (LREC)</h5>
               </div>
               <p>Ethical approval was obtained from the research and ethics committee of the Pakistan
                  Institute of Learning and Living and was submitted to the funding body, Stanley Medical
                  Research Institute.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h5>Data and Safety Monitoring Board (DSMB)</h5>
               </div>
               <p>The DSMB will be constituted according to NIH guidelines, for oversight and monitoring
                  of the conduct of clinical trial. DSMB will meet every 6 months to ensure the safety
                  of participants and the validity and integrity of the data.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h5>Declaration of Helsinki</h5>
               </div>
               <p>The research study will be performed in accordance with the guidelines in the Declaration
                  of Helsinki (1974) as revised in Tokyo (1975), Venice (1983), Hong Kong (1989), South
                  Africa (1996) and Scotland (2000).
               </p>
               <p>All members of the research team will comply with ICH/GCP Guidelines (1996), which
                  are consistent with principles that have their origin in the Declaration of Helsinki.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h5>Team expertise</h5>
               </div>
               <p>Five of the investigators have extensive experience in treatment and management of
                  schizophrenia (Chaudhry, Haddad, Husain, Kazmi, Rahman and Deakin). Kazmi and Rahman
                  as local investigators will be important components of success in recruitment. All
                  investigators have been closely involved in setting up the methodology and software
                  for gathering clinical and research data in patients with psychosis. Chaudhry and
                  Husain will oversee the training of RAs in recruiting patients and in diagnostic and
                  symptom ratings. All of the investigators were involved in feasibility study for this
                  trial. Deakin, Haddad and Chaudhry are experts in psychopharmacology. Chaudhry and
                  Husain have been PIs in a number of multicentre trials funded by the Medical Research
                  Council (MRC) and SMRI in schizophrenia and have much experience of large-scale treatment
                  studies in psychosis. Chaudhry and Husain have published longitudinal studies on negative
                  symptoms, cognition and quality of life. Husain, Chaudhry, Kazmi, Rahman and colleagues
                  ran the SMRI trial of minocycline.
               </p>
            </div>
         </div>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Discussion</h2>
      </div>
      <p>Evidence suggests inflammatory processes are involved in the pathogenesis of schizophrenia
         and anti-inflammatory treatments have shown to have some beneficial effects. MXT is
         a known immuno-suppressant and anti-inflammatory drug. The aim of the this study is
         to evaluate the effectiveness of MXT added to TAU on positive and negative symptoms,
         cognitive and social functioning and quality of life of patients suffering from schizophrenia.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Trial status</h2>
      </div>
      <p>This clinical trial was registered in February of 2014. The study is currently recruiting
         participants. The estimated study completion date is December 2015. Please refer to
         this study by its ClinicalTrials.gov identifier: NCT02074319.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Abbreviations</h2>
      </div>
      <p>ANCOVA: analysis of covariance; ANNSERS: Antipsychotic Non-Neurological Side-Effects
         Rating Scale; BDNF: brain-derived neurotrophic factor; BMI: body Mass Index; BP: blood
         Pressure; CGI: Clinical Global Impression; CRP: C-reactive protein; DHFR: dihydrofolate
         reductase; DSMB: Data and Safety Monitoring Board; DSM-IV-TR: 
         <i>Diagnostic and Statistical Manual-IV-text revision</i>; ECG: electrocardiogram; FBC: full blood count; GAF: Global Assessment of Functioning;
         GCP: Good Clinical Practice; GEE: generalised estimating equations; ICD-10: 
         <i>International Statistical Classification of Diseases and Related Health Problems</i>; ICH: International Conference for Harmonisation; IFN-gamma: interferon-gamma; IL:
         interleukin; IL-1RA: interleukin 1 receptor antagonist; IQ: Intelligence Quotient,
         ITT, intention-to-treat; LFTs: liver function tests; LREC: Local Research Ethics Committee;
         MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia;
         MDT: multi-disciplinary teams; MRC: Medical Research Council; MXT: methotrexate; NMDA:
         N-methyl-D-aspartate; NO: nitric oxide; PANSS: Positive and Negative Syndrome Scale;
         PET: positron emission tomography; PI: principal investigator; QLS: Quality of Life
         Scale; QOL: quality of life; RA: research assistants; RMO: resident medical officer;
         ROS: reactive oxygen species; SFS: Social Functioning Scale; SCID: Structured Clinical
         Interview for DSM-IV; sIL-2R: soluble IL-2 receptor; SMRI: Stanley Medical Research
         Institute; TAU: treatment as usual; TNF-alpha: tumour necrosis factor-alpha; TRS:
         Treatment Resistant Schizophrenia; UK: United Kingdom; WAIS: Wechsler Adult Intelligence
         Scale.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Competing interests</h2>
      </div>
      <p>IBC, JFWD, PH and NH have given lectures and advice to Lilly, Bristol Myers Squibb,
         Lundbeck, Astra Zeneca and Janssen pharmaceuticals for which they or their employing
         institution have been reimbursed. None of the companies they have worked with have
         a financial interest in this research. All other authors have no reported conflicts
         of interest.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Authors’ contributions</h2>
      </div>
      <p>IBC has extensive experience of clinical trials and management of schizophrenia, conceived
         the study, participated in its design and draft the manuscript. NH has extensive experience
         of clinical trials and management of schizophrenia, conceived the study, participated
         in its design and draft the manuscript. RR contributed to design and methodology of
         study, supervision and training of RAs, has extensive experience of clinical trials
         and management of schizophrenia. MOH contributed to design and methodology and writing
         of manuscript. MH contributed to design and methodology of study, supervision and
         training of RAs, has extensive experience of clinical trials and management of schizophrenia.
         AK contributed to design and methodology of study, supervision and training of RAs,
         has extensive experience in management of schizophrenia. SB has extensive experience
         in use of methotrexate, helped conceive the study and is involved in setting up the
         drug related components of trial such as dose, potency, and adverse effect monitoring.
         PMH has extensive experience of clinical trials and management of schizophrenia, contributed
         to design and methodology of the study. MB is clinical trialist of biologic therapies
         and translational research of autoimmune diseases, contributed to design and was closely
         involved in setting up the drug related components of trial like dose, potency, and
         adverse effect monitoring. IQ contributed to design and methodology and writing of
         manuscript. NM contributed to methodology and procedure, was involved in screening,
         recruitment and assessment. TK contributed to methodology and procedure, was involved
         in screening, recruitment and assessment. BF is a biostatistician and is involved
         in designing trial statistical methodology. SA has extensive experience of use of
         methotrexate and contributed to methodology of the study. JFWD has extensive experience
         of clinical trials and management of schizophrenia, conceived the study, participated
         in its design and methodology. All authors read and approved the final manuscript.
      </p>
   </div>
   <div tagx="bm">
      <div tagx="ack">
         <div id="">
            <div tagx="st">
               <h2>Acknowledgments</h2>
            </div>
            <p>This research was funded by the Stanley Medical Research Institute (SMRI). We would
               like to thank Pakistan Institute of Living and Learning for their logistical support.
            </p>
         </div>
      </div>
      <div tagx="refgrp">
         <div tagx="bibl">
            <div tagx="title">
               <p>Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Cronstein</span>
                  <span tagx="fnm">BN</span>
               </li>
            </ul>
            <span tagx="source">Pharmacol Rev</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">57</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">163</span>
            <span tagx="lpage">72</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1124/pr.57.2.3</span>
                  <span tagx="pubid">15914465</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule
                  kinetics
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Ravi Rajagopalan</span>
                  <span tagx="fnm">PT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">Z</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McCourt</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dwyer</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Benkovic</span>
                  <span tagx="fnm">SJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hammes</span>
                  <span tagx="fnm">G</span>
               </li>
            </ul>
            <span tagx="source">Proc Natl Acad Sci</span>
            <span tagx="pubdate">2002</span>
            <span tagx="volume">99</span>
            <span tagx="issue">21</span>
            <span tagx="fpage">13481</span>
            <span tagx="lpage">6</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1073/pnas.172501499</span>
                  <span tagx="pubid">129699</span>
                  <span tagx="pubid">12359872</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis,
                  but by the suppression of activation and adhesion molecules
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Johnston</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gudjonsson</span>
                  <span tagx="fnm">JE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sigmundsdottir</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Runar Ludviksson</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Valdimarsson</span>
                  <span tagx="fnm">H</span>
               </li>
            </ul>
            <span tagx="source">Clin Immunol</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">114</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">154</span>
            <span tagx="lpage">63</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.clim.2004.09.001</span>
                  <span tagx="pubid">15639649</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic
                  heart failure
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Gong</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">Z</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sun</span>
                  <span tagx="fnm">X</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">X</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Li</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Yan</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Luo</span>
                  <span tagx="fnm">Q</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gao</span>
                  <span tagx="fnm">Y</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Feng</span>
                  <span tagx="fnm">Y</span>
               </li>
            </ul>
            <span tagx="source">Am Heart J</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">151</span>
            <span tagx="issue">1</span>
            <span tagx="fpage">62</span>
            <span tagx="lpage">8</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.ahj.2005.02.040</span>
                  <span tagx="pubid">16368293</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Effects of methotrexate on plasma cytokines and cardiac remodeling and function in
                  postmyocarditis rats
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">Z</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhao</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Li</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lv</span>
                  <span tagx="fnm">X</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gao</span>
                  <span tagx="fnm">Y</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sun</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ding</span>
                  <span tagx="fnm">Y</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Liu</span>
                  <span tagx="fnm">J</span>
               </li>
            </ul>
            <span tagx="source">Mediators Inflamm</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">389720</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Different distribution patterns of lymphocytes and microglia in the hippocampus of
                  patients with residual versus paranoid schizophrenia: further evidence for disease
                  course-related immune alterations?
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Busse</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Busse</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schiltz</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bielau</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gos</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brisch</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mawrin</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schmitt</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jordan</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Müller</span>
                  <span tagx="fnm">UJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bernstein</span>
                  <span tagx="fnm">HG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bogerts</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Steiner</span>
                  <span tagx="fnm">J</span>
               </li>
            </ul>
            <span tagx="source">Brain Behav Immun</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">26</span>
            <span tagx="issue">8</span>
            <span tagx="fpage">1273</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.bbi.2012.08.005</span>
                  <span tagx="pubid">22917959</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind
                  placebo-controlled clinical trial in patients on standard treatment
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Chaudhry</span>
                  <span tagx="fnm">IB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hallak</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Husain</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Minhas</span>
                  <span tagx="fnm">F</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Stirling</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Richardson</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dursun</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dunn</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Deakin</span>
                  <span tagx="fnm">B</span>
               </li>
            </ul>
            <span tagx="source">J Psychopharmacol</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">26</span>
            <span tagx="issue">9</span>
            <span tagx="fpage">1185</span>
            <span tagx="lpage">93</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1177/0269881112444941</span>
                  <span tagx="pubid">22526685</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Potvin</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Stip</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sepehry</span>
                  <span tagx="fnm">AA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gendron</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bah</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kouassi</span>
                  <span tagx="fnm">E</span>
               </li>
            </ul>
            <span tagx="source">Biol Psychiatry</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">63</span>
            <span tagx="issue">8</span>
            <span tagx="fpage">801</span>
            <span tagx="lpage">8</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.biopsych.2007.09.024</span>
                  <span tagx="pubid">18005941</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical
                  and preclinical stages
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Mansur</span>
                  <span tagx="fnm">RB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zugman</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Asevedo</span>
                  <span tagx="fnm">EM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">da Cunha</span>
                  <span tagx="fnm">GR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bressan</span>
                  <span tagx="fnm">RA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brietzke</span>
                  <span tagx="fnm">E</span>
               </li>
            </ul>
            <span tagx="source">Psychiatry Clin Neurosci</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">66</span>
            <span tagx="issue">4</span>
            <span tagx="fpage">247</span>
            <span tagx="lpage">60</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1111/j.1440-1819.2012.02354.x</span>
                  <span tagx="pubid">22624729</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic
                  effects
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Miller</span>
                  <span tagx="fnm">BJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Buckley</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Seabolt</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mellor</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kirkpatrick</span>
                  <span tagx="fnm">B</span>
               </li>
            </ul>
            <span tagx="source">Biol Psychiatry</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">70</span>
            <span tagx="fpage">663</span>
            <span tagx="lpage">71</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.biopsych.2011.04.013</span>
                  <span tagx="pubid">4071300</span>
                  <span tagx="pubid">21641581</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Behrens</span>
                  <span tagx="fnm">MM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ali</span>
                  <span tagx="fnm">SS</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dugan</span>
                  <span tagx="fnm">LL</span>
               </li>
            </ul>
            <span tagx="source">J Neurosci</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">28</span>
            <span tagx="fpage">13957</span>
            <span tagx="lpage">66</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1523/JNEUROSCI.4457-08.2008</span>
                  <span tagx="pubid">2752712</span>
                  <span tagx="pubid">19091984</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain derived
                  neurotrophic factor in human monocytes
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Schulte-Herbruggen</span>
                  <span tagx="fnm">O</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nassenstein</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lommatzsch</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Quarcoo</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Renz</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Braun</span>
                  <span tagx="fnm">A</span>
               </li>
            </ul>
            <span tagx="source">J Neuroimmunol</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">160</span>
            <span tagx="fpage">204</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.jneuroim.2004.10.026</span>
                  <span tagx="pubid">15710474</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Cytokines in schizophrenia and the effects of antipsychotic drugs</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Drzyzga</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Obuchowicz</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Marcinowska</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Herman</span>
                  <span tagx="fnm">ZS</span>
               </li>
            </ul>
            <span tagx="source">Brain Behav Immun</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">20</span>
            <span tagx="issue">6</span>
            <span tagx="fpage">532</span>
            <span tagx="lpage">45</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.bbi.2006.02.002</span>
                  <span tagx="pubid">16580814</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Glial cells in schizophrenia: pathophysiological significance and possible consequences
                  for therapy
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bernstein</span>
                  <span tagx="fnm">HG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Steiner</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bogerts</span>
                  <span tagx="fnm">B</span>
               </li>
            </ul>
            <span tagx="source">Expert Rev Neurother</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">9</span>
            <span tagx="fpage">1059</span>
            <span tagx="lpage">71</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1586/ern.09.59</span>
                  <span tagx="pubid">19589054</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Cytokines and schizophrenia: microglia hypothesis of schizophrenia</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Monji</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kato</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kanba</span>
                  <span tagx="fnm">S</span>
               </li>
            </ul>
            <span tagx="source">Psychiatry Clin Neurosci</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">63</span>
            <span tagx="fpage">257</span>
            <span tagx="lpage">65</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1111/j.1440-1819.2009.01945.x</span>
                  <span tagx="pubid">19579286</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Kynurenines: from the perspective of major psychiatric disorders</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Myint</span>
                  <span tagx="fnm">AM</span>
               </li>
            </ul>
            <span tagx="source">FEBS J</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">2009</span>
            <span tagx="issue">279</span>
            <span tagx="fpage">1375</span>
            <span tagx="lpage">85</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Neuroinflammation in schizophrenia-related psychosis: a PET study</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Doorduin</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">de Vries</span>
                  <span tagx="fnm">EF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Willemsen</span>
                  <span tagx="fnm">AT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">de Groot</span>
                  <span tagx="fnm">JC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dierckx</span>
                  <span tagx="fnm">RA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Klein</span>
                  <span tagx="fnm">HC</span>
               </li>
            </ul>
            <span tagx="source">J Nucl Med</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">50</span>
            <span tagx="fpage">1801</span>
            <span tagx="lpage">7</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.2967/jnumed.109.066647</span>
                  <span tagx="pubid">19837763</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195
                  positron emission tomography study
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">van Berckel</span>
                  <span tagx="fnm">BN</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bossong</span>
                  <span tagx="fnm">MG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Boellaard</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kloet</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schuitemaker</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Caspers</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Luurtsema</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Windhorst</span>
                  <span tagx="fnm">AD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cahn</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lammertsma</span>
                  <span tagx="fnm">AA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kahn</span>
                  <span tagx="fnm">RS</span>
               </li>
            </ul>
            <span tagx="source">Biol Psychiatry</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">64</span>
            <span tagx="fpage">820</span>
            <span tagx="lpage">2</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.biopsych.2008.04.025</span>
                  <span tagx="pubid">18534557</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The positive and negative syndrome scale (PANSS) for schizophrenia</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Kay</span>
                  <span tagx="fnm">SR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fiszbein</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Opler</span>
                  <span tagx="fnm">LA</span>
               </li>
            </ul>
            <span tagx="source">Schizophr Bull</span>
            <span tagx="pubdate">1987</span>
            <span tagx="volume">13</span>
            <span tagx="fpage">261</span>
            <span tagx="lpage">76</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1093/schbul/13.2.261</span>
                  <span tagx="pubid">3616518</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <div tagx="cnm">American Psychiatric Association</div>
               </li>
            </ul>
            <span tagx="source">Diagnostic and statistical manual of mental disorders</span>
            <div tagx="publisher">Washington, DC: American Psychiatric Association</div>
            <div tagx="edition">4</div>
            <span tagx="pubdate">2000</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The development and validation of a new scale of social adjustment for use in family
                  intervention programmes with schizophrenic patients
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Birchwood</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <div tagx="cnm">The Social Functioning Scale</div>
               </li>
            </ul>
            <span tagx="source">Br J Psychiatry</span>
            <span tagx="pubdate">1990</span>
            <span tagx="volume">157</span>
            <span tagx="fpage">853</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1192/bjp.157.6.853</span>
                  <span tagx="pubid">2289094</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The quality of life scale: an instrument for rating the schizophrenic deficit syndrome</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Heinrichs</span>
                  <span tagx="fnm">DW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hanlon</span>
                  <span tagx="fnm">TE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Carpenter</span>
                  <span tagx="fnm">WT</span>
               </li>
            </ul>
            <span tagx="source">Schizophr Bull</span>
            <span tagx="pubdate">1984</span>
            <span tagx="volume">10</span>
            <span tagx="fpage">388</span>
            <span tagx="lpage">98</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1093/schbul/10.3.388</span>
                  <span tagx="pubid">6474101</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Inter-rater reliability of the antipsychotic non-neurological side-effects rating
                  scale (ANNSERS)
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Yusufi</span>
                  <span tagx="fnm">BZ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mukherjee</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Aitchison</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dunn</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Page</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Barnes</span>
                  <span tagx="fnm">TR</span>
               </li>
            </ul>
            <span tagx="source">Abstracts of the XX International Congress on Schizophrenia Research, April 2 – April
               6, 2005, Volume 31
            </span>
            <div tagx="publisher">Savannah, Georgia: Schizophr Bull</div>
            <span tagx="pubdate">2005</span>
            <span tagx="fpage">574</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Whittle</span>
                  <span tagx="fnm">SL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hughes</span>
                  <span tagx="fnm">RA</span>
               </li>
            </ul>
            <span tagx="source">Rheumatology</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">43</span>
            <span tagx="fpage">267</span>
            <span tagx="lpage">71</span>
            <div tagx="xrefbib">
               <span tagx="pubid">14963199</span>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal
                  toxicity in rheumatoid arthritis: a meta-analysis of randomised controlled trials
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Ortiz</span>
                  <span tagx="fnm">Z</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Shea</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Suarez-Almazor</span>
                  <span tagx="fnm">ME</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Moher</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wells</span>
                  <span tagx="fnm">GA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tugwell</span>
                  <span tagx="fnm">P</span>
               </li>
            </ul>
            <span tagx="source">J Rheumatol</span>
            <span tagx="pubdate">1998</span>
            <span tagx="volume">25</span>
            <span tagx="fpage">36</span>
            <span tagx="lpage">43</span>
            <div tagx="xrefbib">
               <span tagx="pubid">9458200</span>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis:
                  a double-blind placebo-controlled trial
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Morgan</span>
                  <span tagx="fnm">SL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Baggott</span>
                  <span tagx="fnm">JE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Vaughn</span>
                  <span tagx="fnm">WH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Austin</span>
                  <span tagx="fnm">JS</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Veitch</span>
                  <span tagx="fnm">TA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lee</span>
                  <span tagx="fnm">JY</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Koopman</span>
                  <span tagx="fnm">WJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Krumdieck</span>
                  <span tagx="fnm">CL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Alarcón</span>
                  <span tagx="fnm">GS</span>
               </li>
            </ul>
            <span tagx="source">Ann Intern Med</span>
            <span tagx="pubdate">1994</span>
            <span tagx="volume">121</span>
            <span tagx="fpage">833</span>
            <span tagx="lpage">41</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.7326/0003-4819-121-11-199412010-00002</span>
                  <span tagx="pubid">7978695</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Enhancement of recovery from psychiatric illness by methylfolate</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Procter</span>
                  <span tagx="fnm">A</span>
               </li>
            </ul>
            <span tagx="source">Br J Psychiatry</span>
            <span tagx="pubdate">1991</span>
            <span tagx="volume">159</span>
            <span tagx="fpage">271</span>
            <span tagx="lpage">2</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1192/bjp.159.2.271</span>
                  <span tagx="pubid">1773245</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Harmonised Tripartite Guideline for Good Clinical Practice 1996</p>
            </div>
            <div tagx="publisher">Geneva: International Federation of the Pharmaceutical Manufacturers Association</div>
            <span tagx="pubdate">1996</span>
         </div>
      </div>
   </div>
</html>